Please use this identifier to cite or link to this item:
Title: Zebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer
Author: Ali, Zaheer
Vildevall, Malin
Vazquez Rodriguez, Gabriela
Tandiono, Decky
Vamvakaris, Ioannis
Evangelou, Georgios
Lolas, Georgios
Syrigos, Konstantinos N.
Villanueva, Alberto
Wick, Michael
Omar, Shenga
Erkstam, Anna
Schueler, Julia
Fahlgren, Anna
Jensen, Lasse D.
Keywords: Càncer de pulmó
Malalts de càncer
Lung cancer
Cancer patients
Issue Date: 9-Feb-2022
Publisher: Springer Science and Business Media LLC
Abstract: Background Accurate predictions of tumor dissemination risks and medical treatment outcomes are critical to personalize therapy. Patient-derived xenograft (PDX) models in mice have demonstrated high accuracy in predicting therapeutic outcomes, but methods for predicting tumor invasiveness and early stages of vascular/lymphatic dissemination are still lacking. Here we show that a zebrafish tumor xenograft (ZTX) platform based on implantation of PDX tissue fragments recapitulate both treatment outcome and tumor invasiveness/dissemination in patients, within an assay time of only 3 days. Methods Using a panel of 39 non-small cell lung cancer PDX models, we developed a combined mouse-zebrafish PDX platform based on direct implantation of cryopreserved PDX tissue fragments into zebrafish embryos, without the need for pre-culturing or expansion. Clinical proof-of-principle was established by direct implantation of tumor samples from four patients. Results The resulting ZTX models responded to Erlotinib and Paclitaxel, with similar potency as in mouse-PDX models and the patients themselves, and resistant tumors similarly failed to respond to these drugs in the ZTX system. Drug response was coupled to elevated expression of EGFR, Mdm2, Ptch1 and Tsc1 (Erlotinib), or Nras and Ptch1 (Paclitaxel) and reduced expression of Egfr, Erbb2 and Foxa (Paclitaxel). Importantly, ZTX models retained the invasive phenotypes of the tumors and predicted lymph node involvement of the patients with 91% sensitivity and 62% specificity, which was superior to clinically used tests. The biopsies from all four patient tested implanted successfully, and treatment outcome and dissemination were quantified for all patients in only 3 days. Conclusions We conclude that the ZTX platform provide a fast, accurate, and clinically relevant system for evaluation of treatment outcome and invasion/dissemination of PDX models, providing an attractive platform for combined mouse-zebrafish PDX trials and personalized medicine.
Note: Reproducció del document publicat a:
It is part of: Journal of Experimental & Clinical Cancer Research, 2022, vol. 41, num. 58
Related resource:
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
s13046-022-02280-x.pdf8.92 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons